急性巨核细胞白血病染色体1q异常高频出现且预后极差
该研究回顾性分析38例成人急性巨核细胞白血病(AMKL)患者(中位年龄58岁,范围21-80岁),多数于2001至2016年间在AML协作组(AMLCG)试验中接受强化治疗。结果显示按ELN 2017标准不良风险标志累积,染色体臂1q结构异常频率高达33%,接受异基因造血干细胞移植(allo-HSCT)者(n=14)中位总生存68周优于未移植者,但移植后累积复发率高达62%。
要点
- 成人AMKL中染色体臂1q结构异常频率意外高达33%。
- 接受强化化疗的33例患者完全缓解率仅33%,中位总生存33周。
- 接受allo-HSCT者(n=14)中位总生存68周,但累积复发率62%。
核心结论
- AMKL的预后由不良遗传风险因素和治疗耐药决定。
- 迄今为止allo-HSCT是这一预后极差的AML亚组中唯一可能治愈的治疗选择。
研究设计与样本
- 回顾性分析38例成人AMKL患者(中位年龄58岁,范围21-80岁),多数于2001至2016年间在AML协作组(AMLCG)试验中接受强化治疗。
主要发现
- 细胞遗传学数据显示按ELN 2017标准不良风险标志累积,染色体臂1q结构异常频率意外高达33%。
- 突变最常见于TET2(23%)、TP53(23%)、JAK2(19%)、PTPN11(19%)和RUNX1(15%)。
- 接受强化化疗的33例患者完全缓解率为33%,中位总生存33周(95% CI:21-45)。
- 接受allo-HSCT者(n=14)中位总生存68周(95% CI:11-126),无复发生存27周(95% CI:4-50),但移植后累积复发率高达62%。
临床怎么用
- 原文结论指出allo-HSCT是这一预后极差的AML亚组中唯一可能治愈的治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute megakaryoblastic leukaemia (AMKL) is associated with poor prognosis. Limited information is available on its cytogenetics, molecular genetics and clinical outcome. We performed genetic analyses, evaluated prognostic factors and the value of allogeneic haematopoietic stem cell transplantation (allo-HSCT) in a homogenous adult AMKL patient cohort. We retrospectively analysed 38 adult patients with AMKL (median age: 58 years, range: 21-80). Most received intensive treatment in AML Cooperative Group (AMLCG) trials between 2001 and 2016. Cytogenetic data showed an accumulation of adverse risk markers according to ELN 2017 and an unexpected high frequency of structural aberrations on chromosome arm 1q (33%). Most frequently, mutations occurred in TET2 (23%), TP53 (23%), JAK2 (19%), PTPN11 (19%) and RUNX1 (15%). Complete remission rate in 33 patients receiving intensive chemotherapy was 33% and median overall survival (OS) was 33 weeks (95% CI: 21-45). Patients undergoing allo-HSCT (n = 14) had a superior median OS (68 weeks; 95% CI: 11-126) and relapse-free survival (RFS) of 27 weeks (95% CI: 4-50), although cumulative incidence of relapse after allo-HSCT was high (62%). The prognosis of AMKL is determined by adverse genetic risk factors and therapy resistance. So far allo-HSCT is the only potentially curative treatment option in this dismal AML subgroup.
引用
- Pastore F, Gittinger H, Raab S, et al. Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome. Br J Haematol. 2023. PMID: 37455345. doi:10.1111/bjh.18982
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。